Vera Bril*, Marta Banach, Marinos C. Dalakas, Chunqin Deng, Peter Donofrio, Kim Hanna, Hans-Peter Hartung, Richard A. C. Hughes, Hans Katzberg, Norman Latov, Ingemar S. J. Merkies, Pieter A. van Doorn

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

45 Citations (Web of Science)


Data are lacking on correlations between changes in nerve conduction (NC) studies and treatment response in chronic inflammatory demyelinating polyneuropathy (CIDP). This report examined data from a randomized, double-blind trial of immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C [Gamunex]; n = 59) versus placebo (n = 58) every 3 weeks for up to 24 weeks in CIDP. Motor NC results and clinical measures were assessed at baseline and endpoint/week 24. Improvement from baseline in adjusted inflammatory neuropathy cause and treatment score correlated with improvement in proximally evoked compound muscle action potential (CMAP) amplitudes (r = -0.53; P <0.001) of all nerves tested and with improvement in CMAP amplitude of the most severely affected motor nerve (r = -0.36; P <0.001). Correlations were observed between improvement in averaged CMAP amplitudes and dominant-hand grip strength (r = 0.44; P <0.001) and Medical Research Council sum score (r = 0.38; P <0.001). Overall, the change in electrophysiologic measures of NC in CIDP correlated with clinical response to treatment.
Original languageEnglish
Pages (from-to)492-497
JournalMuscle & Nerve
Issue number4
Publication statusPublished - Oct 2010


  • polyradiculoneuropathy
  • chronic inflammatory demyelinating
  • clinical trial
  • peripheral nervous system diseases
  • polyneuropathies

Cite this